1,741
Views
1
CrossRef citations to date
0
Altmetric
Short Communicatios

Monomeric α-synuclein (αS) inhibits amyloidogenesis of human prion protein (hPrP) by forming a stable αS-hPrP hetero-dimer.

, , ORCID Icon, , , & show all
Pages 37-43 | Received 13 Jan 2021, Accepted 24 Mar 2021, Published online: 14 Apr 2021

Figures & data

Figure 1. (a) HS-AFM image of hPrP showing various heterogeneous oligomeric states distributed from monomers to hexamers. (b) Typical hexameric oligomer of hPrP with a tail

Figure 1. (a) HS-AFM image of hPrP showing various heterogeneous oligomeric states distributed from monomers to hexamers. (b) Typical hexameric oligomer of hPrP with a tail

Figure 2. HS-AFM images of αS showing (a) globular conformation and (b) extended conformation of αS

Figure 2. HS-AFM images of αS showing (a) globular conformation and (b) extended conformation of αS

Figure 3. (a) HS-AFM image of hPrP and αS complex at equilibrium. (b) Height analysis showed the oligomer at equilibrium was a dimer

Figure 3. (a) HS-AFM image of hPrP and αS complex at equilibrium. (b) Height analysis showed the oligomer at equilibrium was a dimer

Figure 4. Dynamic light scattering (DLS) measurement of a number (population) of particles as a function of particle size (diameter) in (a) hPrP solution with peak at 24 nm, corresponding to an oligomer, (b) αS solution with a diameter of 1.7 nm, corresponding to a monomer, and (c) a mixture of hPrP and αS with a peak at the diameter of 1.7 nm corresponding to a hetero-dimer of hPrP and αS

Figure 4. Dynamic light scattering (DLS) measurement of a number (population) of particles as a function of particle size (diameter) in (a) hPrP solution with peak at 24 nm, corresponding to an oligomer, (b) αS solution with a diameter of 1.7 nm, corresponding to a monomer, and (c) a mixture of hPrP and αS with a peak at the diameter of 1.7 nm corresponding to a hetero-dimer of hPrP and αS

Figure 5. (a) [Citation1H-Citation15]N HSQC spectra of 200 µM [Citation15]N labelled hPrP without (blue) or with 220 µM non-labelled αS (red) at pH 6.1 in 99% H2O/1% D2O. (b) [Citation1H-Citation15]N HSQC spectra of 206 µM [Citation15]N labelled αS without (blue) or with 173 µM non-labelled hPrP (red) at pH 4.6 in 99% H2O/1% D2O

Figure 5. (a) [Citation1H-Citation15]N HSQC spectra of 200 µM [Citation15]N labelled hPrP without (blue) or with 220 µM non-labelled αS (red) at pH 6.1 in 99% H2O/1% D2O. (b) [Citation1H-Citation15]N HSQC spectra of 206 µM [Citation15]N labelled αS without (blue) or with 173 µM non-labelled hPrP (red) at pH 4.6 in 99% H2O/1% D2O

Figure 6. Possible mechanism of suppression of the pathogenic conversion of hPrP by αS. Monomeric αS can trap the intermediate state hPrP and forms a stable hetero-dimer, depleting the available monomeric hPrP for pathogenic conversion

Figure 6. Possible mechanism of suppression of the pathogenic conversion of hPrP by αS. Monomeric αS can trap the intermediate state hPrP and forms a stable hetero-dimer, depleting the available monomeric hPrP for pathogenic conversion
Supplemental material

Supplemental Material

Download MS Word (12.1 KB)